We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| 4basebio Plc | LSE:4BB | London | Ordinary Share | GB00BMCLYF79 | ORD EUR1.00 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,125.00 | 348 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,100.00 | 1,150.00 | 1,125.00 | 1,125.00 | 1,125.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 984k | -7.67M | -0.6222 | -18.08 | 138.59M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:58:44 | O | 1 | 1,100.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/4/2025 | 12:00 | UKREG | 4basebio Plc - Director Dealing |
| 02/4/2025 | 09:51 | ALNC |  IN BRIEF: 4basebio hits "critical milestone" as it secures GMP licence |
| 02/4/2025 | 07:00 | UKREG | 4basebio Plc - 4basebio Receives GMP Licence for its UK DNA Manufacturing.. |
| 25/3/2025 | 10:15 | UKREG | 4basebio Plc - Holding(s) in Company |
| 14/3/2025 | 07:00 | UKREG | 4basebio Plc - RBC Capital Markets initiates research coverage |
| 07/3/2025 | 07:00 | UKREG | 4basebio Plc - Employee Long Term Incentive Plan and Issue of Equity |
| 03/3/2025 | 16:37 | UKREG | 4basebio Plc - Director's Dealing |
| 08/1/2025 | 11:47 | ALNC | IN BRIEF: 4basebio names Gabe Longoria as new chief commercial officer |
| 08/1/2025 | 07:00 | UKREG | 4basebio Plc - Appointment of Chief Commercial Officer |
| 17/12/2024 | 07:00 | UKREG | 4basebio Plc - Directorate Change |
4basebio (4BB) Share Charts1 Year 4basebio Chart |
|
1 Month 4basebio Chart |
Intraday 4basebio Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 30/7/2024 | 08:29 | 4BaseBio - Innovation in Gene Synthesis and Delivery | 100 |
| 21/2/2021 | 20:07 | 4BaseBio | 14 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 24/5/2025 09:20 by 4basebio Daily Update 4basebio Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 4BB. The last closing price for 4basebio was 1,125p.4basebio currently has 12,319,473 shares in issue. The market capitalisation of 4basebio is £138,594,071. 4basebio has a price to earnings ratio (PE ratio) of -18.08. This morning 4BB shares opened at 1,125p |
Posted at 30/7/2024 08:17 by philly cheesesteak Am I the only one that's seen this hugely exciting news? £40m invested at a premium to a share price which has risen 112% YTD is some statement of intent |
Posted at 30/7/2024 08:13 by philly cheesesteak hxxps://polaris.brig"July 29, 2024 - 4basebio PLC (AIM: 4BB) ("4basebio" or the "Company"), which develops and commercialises the large scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announces that it has agreed to binding terms with (i) Elevage Medical Technologies ("Elevage"), a Patient Square Capital platform and (ii) Prudential Assurance Company Limited acting by its investment manager M&G Investment Management Limited ("M&G"), for a combined investment of £40.0 million through an issuance (the "Issuance") of ordinary shares of €1 each at an issue price of 1,500 pence per Ordinary Share (the "Issue Price")." Dr Heikki Lanckriet, CEO and CSO, 4basebio, said: "The evolution of the Group since its spin out at the end of 2020 has been profound. Our client base and pipeline has grown significantly as a result of strong interest in our synthetic DNA products, and we expect client acquisition and revenue generation to continue accelerating. "The capital raise announced today will further drive the momentum of the Company, and I am pleased to see Elevage and M&G join our shareholder register." John Marotta, Executive in Residence, Patient Square Capital, said: "This investment reflects strong conviction in synthetic DNA's potential to advance novel healthcare treatments, and its place as a significant part of the cell and gene therapy market. We are well aligned with the team at 4basebio and are eager to help them reach their next phase of growth with this investment." M&G Portfolio Manager, Jeremy Punnett, said: "The UK has a wealth of innovative deep tech firms that are breaking the mould, but it is vital they get the long-term investment they need to become the next global champions. M&G's Crossover strategy is playing a leading role in helping businesses to scale and thrive by providing expertise and patient capital. "We are delighted to partner with Elevage in supporting 4basebio's pioneering work in synthetic DNA, which underpins the development of cell and gene therapies and offers the potential to transform healthcare and save millions of lives. We look forward to being part of their exciting journey and contributing to the advancement of cutting-edge therapies." |
Posted at 02/2/2024 16:00 by buzzzzzzzz Todays RNS is a clear signal the company is for sale.Question is at what price and what timeframe , CEO and CFO have a great incentive looking at the bonus stated in the RNS. Interesting times! |
Posted at 30/9/2022 07:40 by pob69 Finncap comment;...results reflect consistent progress towards its main objective of producing GMP-grade synthetic DNA, while at the same time it is building incremental value into the business through product/technology expansion with first commercial sales of its DNA and increasing corporate partnerships. It generated revenues of £0.15m with adjusted pre-tax loss of £2.7m (H1 2021: £1.8m, +45%) and ended the period with £5.6m cash. Despite the expected increase in cashburn as headcount increases, near-term funding is not considered an issue, given that it can draw down from its €25m loan facility. ...minor changes to forecasts to reflect increased headcount and higher capex, with year-end cash forecast to be £1.9m (previously £2.3m). We maintain our sum-of-the-parts DCF target price of 1,200p, which is underpinned by the expected high demand for DNA/RNA and the significant potential of its technology to address key challenges in the cell and gene therapy space. |
Posted at 25/7/2022 16:34 by buzzzzzzzz Nice to see the CFO pick up another 5,000 shares in June.Management certainly putting their money where their mouth is! Decent buying today pushing price back up. |
Posted at 15/2/2022 11:02 by buzzzzzzzz Great runs todayProduction will start on schedule and with first commercial order. A real coup nicking cooper from ABCAM he must have faith in 4BB. |
Posted at 09/8/2021 11:00 by buzzzzzzzz Nice to see a little volume today.Consolidation at this level would be nice to see. Interestingly the 2invest share price has risen to 13.30 euro's. So one can buy an inerest in 4BB by buying their shares as 2Invest own 30% of 4BB. Probably talking to myself! |
Posted at 02/8/2021 07:35 by buzzzzzzzz Loving the share price rise on very small volume.Shares obviosly very tightly held, mine are!!! Calling share price £10.00 by Christmas |
Posted at 16/3/2021 18:11 by zurg the indestructible MultibaggerIf the company increased liquidity by raising cash that is not needed it would undoubtedly be by Institutions and not necessarily result in more shares in circulation. as for your ascertation that the share price would be 3x or 4x higher, so what, all it would mean is that the share price has got ahead of itself. What this share needs is news which results in the price rising and tempting holders to sell. The majority of the free float is in German hands and I don't think it would take too much of a rise to tempt them to sell. I am sorry to dissappoint you but I am not a director or management or even an employee but just a shareholder from the initial start up in 2003 and I only have a small holding. I do not understand what you mean by a re run of the Frankfurt listing, that was a merger with Sygnis which was already on the Frankfurt market and there was plenty of liquidity there. If you think the share price should be 3x then why are you not slowly accumulating at these levels? |
Posted at 16/3/2021 15:41 by multibagger I gather a Finncap broker note has been released which may explain a bit of life in the share today. 4BB company is in the right space and at the right time, market sentiment for cutting edge biotech is red hot.However, the lack of liquidity is asphyxiating this share and BoD don't seem to get this. If liquidity issues are ironed out on the UK market, through raising funds (even though funds may not be immediately necessary), then paradoxically I see this trading at 4x or 5x, the share price we are at now. So one of those rare instances when equity dilution and fund raising will actually benefit the share price, contrary to what the BOD think. Time for the major share holders on the BoD to relax and not try to hold on far too tightly to their shares. It is counterproductive. Contrarian thinking one could argue, but could be transformative to unleash the potential of this share. I am sure that the senior people of 4BB from a scientific background, are sharp enough to understand how markets work or how investors/traders think. Or else this UK AIM listing will be a re-run of the Frankfurt all over again.....and then will they consider listing in Paris or Oslo I wonder ? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
